Biocon makes Biocon Biologics a wholly-owned subsidiary via share swap

Listed Co AcquisitionStrategic Transactions View source PDF

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.9%1-day move

₹414.20

prior close

₹416.15

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.9-0.8-0.7-0.8+0.9+1.2+3.3+2.4-2.0-1.9+6.4———

Up moveDown movePending

AI summary

Biocon completed acquisition of 1,15,36,956 equity shares of its material subsidiary Biocon Biologics (BBL) from 127 selling shareholders, making BBL a wholly-owned subsidiary from June 29, 2026. As consideration, Biocon allotted 87,86,362 new equity shares at Rs. 376.41 each on a preferential basis. Share capital rose to Rs. 814.85 crore from Rs. 810.45 crore. Postal ballot approval received on June 7, 2026.

Likely market impact

Slight dilution for existing Biocon shareholders; full ownership of biologics arm, may support future value unlocking or potential listing.